FDA: Cardiac monitoring critical in MS patients taking mitoxantrone

July 31, 2008

FDA also issued a new recommendation for MS patients who have had treatment with mitoxantrone.

Because many multiple sclerosis patients taking mitoxantrone (Novantrone, Immunex) are not having their cardiac functions monitored as recommended, the Food & Drug Administration just sent an alert out to health professionals to remind them of the importance of this task. In addition, the agency issued a new recommendation. All MS patients who have finished treatment with mitoxantrone should receive yearly quantitative left ventricular ejection fraction (LVEF) evaluation to detect late-occurring cardiac toxicity.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, clickhere.